58 results on '"F. Ringeisen"'
Search Results
2. Interaction of GeH 4 with the Ge(100)2 × 1 surface
- Author
-
D. Bolmont, J.J. Koulmann, S. Van, F. Ringeisen, and D. Steinmetz
- Subjects
Sticking coefficient ,Low-energy electron diffraction ,Chemistry ,Analytical chemistry ,chemistry.chemical_element ,Germanium ,Surfaces and Interfaces ,Chemical vapor deposition ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Amorphous solid ,chemistry.chemical_compound ,X-ray photoelectron spectroscopy ,Germane ,Materials Chemistry ,Ultraviolet photoelectron spectroscopy - Abstract
We present photoemission and LEED results concerning the interaction of decomposed germane (GeH 4 *) with a monocrystalline Ge(100)2 x 1 surface. As the sticking coefficient of undecomposed germane on Ge(100) is very weak, we catalytically decompose the germane molecules with a hot tungsten filament. Germanium substrates are heated by the Joule effect in the 20-500°C temperature range and exposed to either catalytically decomposed or undecomposed germane. The crystalline quality of the deposited films is controlled by low energy electron diffraction (LEED) and angle resolved ultraviolet photoelectron spectroscopy (ARUPS). We compare our ARUPS spectra with spectra resulting from the hydrogenation of the Ge(100) surface by means of atomic hydrogen (H*). After exposure of the Ge(100) surface to GeH 4 * at room temperature (RT), the deposited Ge films are submitted to annealings up to 250°C. At RT, the deposited Ge film is amorphous with an ARUPS signature characteristic of a polygermane. After annealing at 250°C, we recover the LEED pattern of the Ge(100)2 x 1 reconstruction. No chemical shift has been evidenced by means of X-ray photoelectron spectroscopy (XPS) between the Ge 3d core level of the deposited Ge film or Ge(100) substrate.
- Published
- 1995
- Full Text
- View/download PDF
3. Growth of a Ge/Si/Ge (100) heterostructure by very low pressure chemical vapour deposition using Si2H6 and GeH4 gases—photoemission and low energy electron diffraction studies
- Author
-
F. Ringeisen, D. Bolmont, D. Steinmetz, J.J. Koulmann, and S. Van
- Subjects
Materials science ,Low-energy electron diffraction ,Photoemission spectroscopy ,Mechanical Engineering ,Analytical chemistry ,Chemical vapor deposition ,Substrate (electronics) ,Condensed Matter Physics ,Epitaxy ,chemistry.chemical_compound ,chemistry ,Mechanics of Materials ,Germane ,General Materials Science ,Disilane ,Thin film - Abstract
We present photoemmision and low energy electron diffraction (LEED) results obtained on a Ge/Si/Ge (100) heterostructure grown by very low pressure chemical vapour deposition of disilane (Si 2 H 6 or germane (GeH 4 on a Ge(100) 2×1 substrate. Both gases were catalytically dissociated at a hot tungsten filament. A thin (about 20 A thick) epitaxic Si film is deposited by means of the CVD technique on an atomatically clean Ge(100) 2×1 substrate by exposing it at 300 °C to a dissociated Si 2 H 6 gas phase. The obtained Si/Ge structure is then submitted to a subsequent dissociated GeH 4 exposure at 250°C to achieve Ge deposition. Growth of the resulting Ge/Si/Ge (100) heterostructure is followed by means of X-ray photoemission spectroscopy, angle-resolved ultraviolet photoemission spectroscopy and LEED. The main and original conclusion of our study is the possibility of Ge growth from a GeH 4 gas phase on top of a thin epitaxic Si layer previously deposited on Ge (100) from an Si 2 H 6 gas phase. Such studies, performed in reproducible ultrahigh vacuum conditions on the very first steps of interface growth, should contribute to a better understanding and control of the various parameters involved in the gas source, molecular beam epitaxial growth of forthcoming Si/Ge heterostructures.
- Published
- 1994
- Full Text
- View/download PDF
4. Thermal and catalytic decomposition of Si2H6 on a Ge(100)2 × 1 surface: Photoemission and LEED studies
- Author
-
J.J. Koulmann, F. Ringeisen, D. Bolmont, D. Steinmetz, and S. Van
- Subjects
Low-energy electron diffraction ,Analytical chemistry ,chemistry.chemical_element ,Angle-resolved photoemission spectroscopy ,Germanium ,Surfaces and Interfaces ,Atmospheric temperature range ,Condensed Matter Physics ,Surfaces, Coatings and Films ,chemistry.chemical_compound ,X-ray photoelectron spectroscopy ,chemistry ,Materials Chemistry ,Disilane ,Thin film ,Ultraviolet photoelectron spectroscopy - Abstract
We present photoemission and LEED results concerning the thermal and catalytic decomposition of disilane Si2H6 on a monocrystalline Ge(100)2 × 1 surface. The catalytic decomposition of disilane was obtained with a hot tungsten filament. Germanium substrates were heated by the Joule effect in the 20–500°C temperature range and exposed to either catalytically decomposed or undecomposed disilane. The thicknesses of the Si deposited layers were estimated from X-ray photoelectron spectroscopy (XPS) measurements. The crystalline quality of the deposited films could be controlled by angle resolved ultraviolet photoelectron spectroscopy (ARUPS), X-ray photoelectron diffraction (XPD) and low energy electron diffraction (LEED). For a substrate temperature around 350°C, the exposures to undecomposed or catalytically decomposed disilane lead to deposition of well-ordered Si thin films. At this substrate temperature, the Si growth rate was found to be 2–3 times higher when disilane was catalytically decomposed. At substrate room temperature, while some authors claimed the adsorption of undecomposed disilane on a Ge(100)2 × 1 surface, our results seem to show that no reaction occurs between undecomposed disilane and a Ge(100)2 × 1 surface. For substrate temperature above 400°C, the decrease of the Si photoemission intensities can be explained by an indiffusion of Si into Ge.
- Published
- 1994
- Full Text
- View/download PDF
5. Condensation of disilane or germane on a metallic surface: a photoemission study
- Author
-
D. Bolmont, F. Ringeisen, S. Van, J.J. Koulmann, and D. Steinmetz
- Subjects
Chemistry ,Hydride ,Condensation ,Binding energy ,Surfaces and Interfaces ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Metal ,chemistry.chemical_compound ,Adsorption ,Germane ,visual_art ,Materials Chemistry ,visual_art.visual_art_medium ,Physical chemistry ,Molecule ,Disilane ,Atomic physics - Abstract
To shed some light on the problem of hydride adsorption on semiconducting surfaces, we have performed a photoemission study to compare gases like disilane (Si 2 H 6 ) and germane (GeH 4 ) in the condensed (or physisorbed) state (−150°C) with disilane and germane in the chemisorbed state (at room temperature). These molecules were condensed on a metallic substrate to minimize the charging effect resulting from the formation of insulating films. X-ray photoemission experiments revealed a shift of about 1.2 eV towards lower binding energies of the Si2s and Ge3d core-level peaks between the condensed state and the adsorbed state. In the chemisorbed state, the energy location of those peaks is the same as in the bulk material. We conclude that Si 2 H 6 and GeH 4 molecules are already chemisorbed on the surface at room temperature. We also found that such a “physisorbed state → chemisorbed state” transition could be induced at low temperature (−150°C) by a 2 keV Ar + ion bombardment of the condensed film. These results are discussed in relation to our previously published conclusions on hydride adsorption on semiconducting surfaces.
- Published
- 1992
- Full Text
- View/download PDF
6. Interfacial reaction between disilane and a Ge(111)c(2 × 8) surface
- Author
-
S. Van, F. Ringeisen, D. Bolmont, D. Steinmetz, and J.J. Koulmann
- Subjects
Materials science ,Photoemission spectroscopy ,Thermal decomposition ,Analytical chemistry ,chemistry.chemical_element ,Germanium ,Surfaces and Interfaces ,Substrate (electronics) ,Atmospheric temperature range ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Monocrystalline silicon ,chemistry.chemical_compound ,X-ray photoelectron spectroscopy ,chemistry ,Materials Chemistry ,Disilane - Abstract
We present photoemission results on the thermal and catalytic decomposition of disilane (Si 2 H 6 ) on a monocrystalline Ge(111)c(2×8) surface. Catalytic decomposition of disilane is obtained at a hot tungsten filament. Germanium substrates were heated by the Joule effect in the 20–600 °C temperature range and exposed to low pressure (10 −5 Torr) Si 2 H 6 doses. The thicknesses of the Si layers deposited by both methods were estimated from X-ray photoemission spectroscopy (XPS) measurements. Valence band ultraviolet photoemission spectroscopy (UPS) is used to characterize the crystalline quality of the deposited films. The growth rate of the Si film is found to be 10 times higher when obtained after catalytic decomposition rather than by thermal decomposition of disilane. For substrate temperatures above 400 °C, we observe a silicon-germanium intermixing.
- Published
- 1991
- Full Text
- View/download PDF
7. Existence and thermal stability of mono and dihydride phases on Si(1 1 1) and Ge(1 1 1) surfaces
- Author
-
D. Bolmont, J.J. Koulmann, F. Ringeisen, and D. Steinmetz
- Subjects
Materials science ,Physical chemistry ,Thermal stability ,Electrical and Electronic Engineering ,Condensed Matter Physics ,Electronic, Optical and Magnetic Materials - Published
- 1991
- Full Text
- View/download PDF
8. Monohydride phase on Ge(111) and amorphous germanium surfaces: a photoemission study
- Author
-
D. Steinmetz, F. Ringeisen, D. Bolmont, and J.J. Koulmann
- Subjects
Hydrogen ,Chemistry ,Inorganic chemistry ,Analytical chemistry ,chemistry.chemical_element ,Germanium ,Surfaces and Interfaces ,Substrate (electronics) ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Amorphous solid ,Adsorption ,Chemisorption ,Phase (matter) ,Thermal ,Materials Chemistry - Abstract
This is a study of the adsorption of hydrogen at various temperatures on Ge(111)c(2 × 8) and amorphous Ge surfaces. We observe that the only phase forming on both surfaces for temperatures above room temperature is a monohydride phase. This phase desorbs completely at 150°C. For high hydrogen exposures, coadsorbed oxygen impurities build up for substrate temperatures below 150°C. The oxygen contamination desorbs completely at 225°C. This thermal evolution allows clear distinction between the monohydride phase and oxygen contamination.
- Published
- 1990
- Full Text
- View/download PDF
9. Adsorption de disilane sur Si(111) 7 × 7. Influence de l'hydrogène
- Author
-
M. Alaoui, J.J. Koulmann, F. Ringeisen, and D. Bolmont
- Subjects
Ge ,Materials science ,Silicon ,Semiconductor materials ,chemistry.chemical_element ,H effects ,02 engineering and technology ,disilane adsorption ,SiH ,01 natural sciences ,chemistry.chemical_compound ,X ray photoelectron spectra ,0103 physical sciences ,monohydride phase ,XPS measurements ,25 to 550 degC ,010302 applied physics ,Ge 111 substrate ,sticking ,SiH sub 2 groups ,silicon ,dihydride phases ,semiconductor ,021001 nanoscience & nanotechnology ,chemistry ,adsorption ,[PHYS.HIST]Physics [physics]/Physics archives ,SiH sub 4 ,Physical chemistry ,Si 1117*7 ,Si ,Disilane ,elemental semiconductors ,room temperature ,silicon compounds ,0210 nano-technology ,SiH sub 2 sub n polysilane - Abstract
L'adsorption de disilane sur Si(111) 7 x 7 dans la gamme de température 25-550 °C fait apparaître la formation des phases mono et dihydrure déjà observées avec les systèmes Si(111) : H et Si(111) : SiH4. La phase monohydrure Si-H est maximale à 350 °C et subsiste jusqu'à 550 °C. La phase dihydrure est très importante à température ambiante (TA), inexistante à partir de 250 °C et traduit la formation d'un polysilane de type (SiH 2)n. Une surface (111) de silicium, saturée en hydrogène ou disilane à 350 °C, est passivée vis-à-vis du disilane à TA. Pour obtenir la formation d'une phase dihydrure, il est nécessaire de casser la molécule de disilane ou d'hydrogène au contact d'un filament de tungstène porté à haute température. Par comparaison avec l'adsorption de disilane sur Ge(111), nous concluons, à partir de mesures XPS, qu'une partie au moins de la phase dihydrure résulte de la fixation de groupements SiH2.
- Published
- 1990
- Full Text
- View/download PDF
10. Photoemission study of low pressure hydrogen and disilane adsorption on Si(111) 7 × 7 and Ge(111)
- Author
-
F. Ringeisen, M. Alaoui, J.J. Koulmann, and D. Bolmont
- Subjects
Silicon ,Hydrogen ,Inorganic chemistry ,Metals and Alloys ,Analytical chemistry ,chemistry.chemical_element ,Surfaces and Interfaces ,Atmospheric temperature range ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,Amorphous solid ,chemistry.chemical_compound ,Adsorption ,chemistry ,X-ray photoelectron spectroscopy ,Materials Chemistry ,Polysilane ,Disilane - Abstract
We report results on the adsorption of hydrogen and disilane on Si(111) 7 × 7 and Ge(111) surfaces studied by ultraviolet and X-ray (XPS) photoemission spectroscopies. Samples were heated in the 20–500°C temperature range and exposed to low pressure (10 −5 torr) H and Si 2 H 6 doses in the 10 3 –10 5 L exposure range. Only characteristic signatures of mono- and dihydride phases are observed. Saturation of a silicon surface with Si 2 H 6 cannot be achieved at room temperature (RT) in contrast with experiments carried out in the same conditions with atomic hydrogen. Results suggest formation of a more or less amorphous polysilane. A Si(111) surface saturated at 300°C with monohydride phase cannot subsequently adsorb Si 2 H 6 at room temperature whereas further hydrogen adsorption is still possible through dihydride phase formation. Dihydride phase formation is possible by disilane cracking at a hot tungsten filament. Disilane adsorption on a Ge(111) surface induces characteristic features of mono- and dihydride phases. No silicon deposit is evidenced by XPS at room temperature. Silicon deposition on the Ge(111) surface requires disilane cracking at a hot tungsten filament. Possible mechanisms explaining the observed results are discussed.
- Published
- 1990
- Full Text
- View/download PDF
11. Using decomposed disilane as a gas source for Si epitaxial growth on Ge (111): Photoemission studies
- Author
-
J.J. Koulmann, D. Bolmont, D. Steinmetz, F. Ringeisen, and S. Van
- Subjects
Amorphous silicon ,chemistry.chemical_compound ,Physics and Astronomy (miscellaneous) ,chemistry ,Catalytic chemical vapor deposition ,Inorganic chemistry ,Analytical chemistry ,Wafer ,Substrate (electronics) ,Growth rate ,Disilane ,Epitaxy ,Layer (electronics) - Abstract
A good Si epitaxial growth rate on Ge (111) has been achieved at substrate temperatures as low as 350 °C thanks to the use of decomposed disilane in the catalytic chemical vapor deposition (CTL‐CVD) method. For substrate temperatures in the (100–200 °C) range, an exposure of the Ge (111) wafer to decomposed disilane led to the formation of an amorphous silicon film. The growth rate of this Si layer was found to be several times higher when using decomposed disilane rather than undecomposed disilane. At substrate temperatures above 400 °C, an interdiffusion of Si into Ge occurred in both cases of disilane and decomposed disilane exposures.
- Published
- 1990
- Full Text
- View/download PDF
12. Room temperature disilane adsorption on Si(111) and Ge(111) studied by UPS: a comparative study
- Author
-
D. Bolmont, M Alaoui, J.J Koulmann, and F Ringeisen
- Subjects
Silicon ,Chemistry ,Radical ,Analytical chemistry ,Dangling bond ,chemistry.chemical_element ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Crystallography ,chemistry.chemical_compound ,Adsorption ,X-ray photoelectron spectroscopy ,Phase (matter) ,Molecule ,Disilane ,Instrumentation - Abstract
Room temperature (RT) adsorption of disilane (Si2H6) on Si(111) andGe(111) surfaces has been studied using uv photoelectron spectroscopy (UPS). Si(111) and Ge(111) substrates were atomically cleaned under uhv conditions and subsequently exposed at room temperature to low pressure (10−5 torr) Si2H6 doses. For both surfaces, only characteristic features or monohydride and polyhydride phases are evidenced. For RT disilane adsorption on Si(111), UPS spectra reveal solely polyhydride phase formation whereas Si2H6 adsorption on Ge(111) induces both mono and polyhydride phases. However, for equivalent exposure doses, UPS features associated to these two phases are significantly weaker on Ge(111) than on Si(111). For RT disilane adsorption on Ge(111), X-ray photoelectron spectroscopy (XPS) reveals no presence of silicon atoms on the Ge surface, even for heavy exposure doses. The monohydride and polyhydride phases are of comparable importance with those obtained by exposing a Ge(111) surface to molecular hydrogen. We conclude that the Ge(111) surface dissociates the H2 molecule. The resulting H radicals saturate the available dangling bonds inhibiting the sticking of H2SiSiH2 radicals. We also checked that molecular hydrogen is not decomposed by the Si(111) surface. In that case, we explain the presence of an important dihydride phase without associated monohydride by the sticking of H2SiSiH2 groups.
- Published
- 1990
- Full Text
- View/download PDF
13. Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome
- Author
-
F, Tronche, F, Ringeisen, M, Blumenfeld, M, Yaniv, and M, Pontoglio
- Subjects
Binding Sites ,Genome ,Databases, Factual ,Oligonucleotides ,Nuclear Proteins ,DNA ,Binding, Competitive ,DNA-Binding Proteins ,Enhancer Elements, Genetic ,Liver ,Multigene Family ,Hepatocyte Nuclear Factor 1 ,Vertebrates ,Animals ,Humans ,Hepatocyte Nuclear Factor 1-alpha ,Promoter Regions, Genetic ,Sequence Alignment ,Hepatocyte Nuclear Factor 1-beta ,Transcription Factors - Abstract
Hepatocyte nuclear factor 1 (HNF1) is a dimeric homeoprotein expressed in hepatocytes and in a few other epithelial cells where it helps regulate the expression of a specific subset of genes. In an attempt to identify novel target genes for HNF1 and to assess the distribution of its target sites within the vertebrate genome, we performed a computer-assisted search within the available databases using a weighted matrix. Several hundred potential target sequences were identified within the GenBank and EMBL data banks. DNA binding assays demonstrated that more than 95%, of the new sites tested (52 sites among 54) bound HNF1. Surprisingly many HNF1 target sites were found in genes that are transcribed in cell types that do not contain the protein. On the other hand these sites are 2.5 to five times more frequent in hepatic genes than expected. It seems that the presence of HNF1 sites in liver-specific genes was favoured, but that no counter-selection occurred within the rest of the genome. HNF1 binding sites in liver genes are more often associated in clusters with sites for other transcription factors and the enrichment is more pronounced in promoter regions. We identified more than 100 liver specific genes that are potentially regulated by HNF1.
- Published
- 1997
14. Photoemission study of the thermal and catalytic decomposition of germane on a Si(111)7 x 7 surface
- Author
-
D. Steinmetz, F. Ringeisen, J. J. Koulmann, D. Bolmont, and S. Van
- Subjects
chemistry.chemical_compound ,Adsorption ,Materials science ,Silicon ,chemistry ,Germane ,Physical chemistry ,chemistry.chemical_element ,Substrate (electronics) ,Heterogeneous catalysis ,Single crystal ,Chemical decomposition ,Catalysis - Abstract
Photoemission techniques have been used to discern the nature of the species involved in the adsorption of germane and catalytically decomposed germane on a Si(111)7\ifmmode\times\else\texttimes\fi{}7 surface. It has been shown that the catalytic decomposition of germane induces--at very low substrate temperature (RT--300 \ifmmode^\circ\else\textdegree\fi{}C)--in the Ge adsorption process, a mechanism quite different from the undecomposed germane adsorption. In this study, GeH, ${\mathrm{GeH}}_{2}$, and ${\mathrm{GeH}}_{3}$ radicals have been experimentally identified.
- Published
- 1991
15. Existence and thermal stability of mono and dihydride phases on Si(1 1 1) and Ge(1 1 1) surfaces
- Author
-
J.J. Koulmann, D. Steinmetz, F. Ringeisen, and D. Bolmont
- Published
- 1991
- Full Text
- View/download PDF
16. Comparative photoemission study of low-pressure hydrogen, silane, and disilane adsorption on Si(111)7 x 7
- Author
-
D. Bolmont, J. J. Koulmann, F. Ringeisen, and M Alaoui
- Subjects
Materials science ,Silicon ,Hydrogen ,Dimer ,chemistry.chemical_element ,Silane ,Crystallography ,chemistry.chemical_compound ,Adsorption ,chemistry ,Chemisorption ,Physics::Atomic and Molecular Clusters ,Disilane ,In situ study - Abstract
We present an in situ study of low-pressure hydrogen, silane, and disilane chemisorption on Si(111) surfaces. Only characteristic signatures of mono and dihydride phases are evidenced. At room temperature sticking of ${\mathrm{SiH}}_{2}$ or (${\mathrm{SiH}}_{2}$${)}_{\mathrm{n}}$ species for ${\mathrm{SiH}}_{4}$ and ${\mathrm{Si}}_{2}$${\mathrm{H}}_{6}$, respectively, are proposed and related to the back bonds of the dimer\char21{}adatom\char21{}stacking-fault model.
- Published
- 1990
17. Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma: Final results of a phase II study
- Author
-
P. Fumoleau, Florence Joly, F. Ringeisen, Pierre Kerbrat, Thierry Petit, Olivier Rixe, Catherine Lhommé, Patricia Pautier, and Philippe Bougnoux
- Subjects
Oncology ,Cancer Research ,Poor prognosis ,medicine.medical_specialty ,Second-line therapy ,business.industry ,Phases of clinical research ,medicine.disease ,Carboplatin ,chemistry.chemical_compound ,Gefitinib ,Paclitaxel ,chemistry ,Multicenter study ,Internal medicine ,medicine ,Adenocarcinoma ,business ,medicine.drug - Abstract
5566 Background: High EGFR expression occurs in 35–70% of primary ovarian tumors and is often associated with poor prognosis. This Phase II, open-label, non-comparative multicenter study investigated the efficacy and tolerability of gefitinib (Iressa) in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma. Methods: Women (>18 years) with platinum-resistant/refractory (relapsed 6 months) disease were enrolled. Pts received gefitinib (500 mg/day), P (175 mg/m2) and C (AUC 5) every 3 weeks for 6–8 cycles, after which pts could continue to receive gefitinib. The primary endpoint was objective response rate (ORR) assessed using RECIST or Rustin criteria. Results: Sixty-eight pts (26 resistant/refractory and 42 sensitive) were enrolled (median age [range]: 57 [34–72] years; ECOG performance status 0/1/2: 41/26/1). ORR and disease control rates were 19.2% and 69.2%, respectively, for resistant/refractory; and 61.9% and 81.0%, respectively, for sensitive pts (see table ). Grade 3/4 toxicities (in =10% pts) were neutropenia (59%), diarrhea (25%), leukopenia (22%), anemia (13%), and acne (13%). Two myelodysplastic syndromes (MDS) and one acute biphenotypic leukemia were observed during treatment. Another pt developed MDS 34 months after study treatment discontinuation. Conclusions: Gefitinib (Iressa) in combination with P and C has promising activity as second-line treatment for ovarian, tubal or peritoneal adenocarcinoma and is generally well tolerated. The hemopathies are under further investigation. [Table: see text] No significant financial relationships to disclose.
- Published
- 2007
- Full Text
- View/download PDF
18. Synovialosarcome primitif du rein de type biphasique : étude de 2 cas confirmés par une étude en biologie moléculaire
- Author
-
G. Saada-sebag, C. Salon, Pasquier D, Basile Pasquier, B. Fabre, F. Ringeisen, Lamia Bensaadi, and L. Guillou
- Subjects
Pathology and Forensic Medicine - Published
- 2006
- Full Text
- View/download PDF
19. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC)
- Author
-
Claude Linassier, M. A. Lefrere-Belda, Jean-Marc Limacher, Stéphane Oudard, F. Ringeisen, M. Baudard, Eugeniu Banu, Olivier Rixe, J. P. Machiels, and Thierry Velu
- Subjects
chemistry.chemical_classification ,Cancer Research ,business.industry ,medicine.medical_treatment ,Phases of clinical research ,Immunotherapy ,medicine.disease ,Oncology ,chemistry ,Antigen ,Renal cell carcinoma ,Immunology ,Medicine ,In patient ,Cancer vaccine ,business ,Glycoprotein ,MUC1 - Abstract
2581 Background: MUC1 is a glycoprotein often over-expressed and underglycosylated in renal cell carcinoma (RCC) making it an attractive antigenic target for tumor-specific immunotherapy. TG4010 is a cancer vaccine based on a modified vaccinia virus, strain MVA, expressing both MUC1 and Interleukin 2 (MVA-MUC1-IL2). The objective of this phase II, non-randomized study was to determine the efficacy of TG4010 alone and in combination with cytokines. Methods: Thirty seven patients (pts) with progressive metastatic RCC expressing MUC1 in at least 50% of the tumour cells were treated by subcutaneous injections of TG4010, 108 pfu/inj weekly, for 6 weeks then every three weeks until progression. At progression, TG4010 was continued in combination with Interferon α2a (INF) and Interleukin 2 (IL2). Results: Treatment efficacy and toxicities were previously presented at ASCO 2005 (abstr 4653). No objective responses have been observed, however, 7 pts (19%) remained stable for more than 6 months with TG4010 alone, 3 of them more than 22 months. After progression on TG4010 alone 22 pts received TG4010 in combination with cytokines. Six pts (27%) have been stabilized more than 6 months. The median TTP were 2.6 months (95% CI, 2.4–2.9 months) for TG4010 alone and 3.5 months (95% CI, 0.2–6.7 months) for the combined treatment. There were 24 deaths, with a median OS of 19 months (95% CI, 10–27.9) for the whole population. Seven pts were treated by sorafenib after immunotherapy failure. After censoring pts at the introduction of sorafenib, the median OS was 16 months (95% CI, 6–26), with 41% of pts alive at 2-years. The most frequent adverse effects related to TG4010 were minor to moderate injection site reactions, fatigue and flu-like symptoms. Twelve out of 24 pts evaluable for MUC1 ELISpot show evidence for MUC1-specific CD8+ T cell response while 14 out of 21 evaluable for MUC1 specific T cell proliferation were responsive. Conclusions: The cancer vaccine TG4010 alone and in combination with IL2 and INF induces some disease stabilizations in pts with progressive metastatic RCC and can improve survival in a population selected for MUC1 positivity, which is a factor of poor prognosis. [Table: see text]
- Published
- 2006
- Full Text
- View/download PDF
20. Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma
- Author
-
Olivier Rixe, F. Ringeisen, Claude Linassier, Bruce Acres, J. P. Machiels, Thierry Velu, Eugeniu Banu, J. F. Rossi, Patrick Squiban, and Stéphane Oudard
- Subjects
Interleukin 2 ,Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,medicine.disease ,Vaccination ,Oncology ,Antigen ,Renal cell carcinoma ,Interferon ,Cancer research ,Medicine ,Cancer vaccine ,business ,neoplasms ,MUC1 ,medicine.drug - Abstract
4653 Background: MUC1 is a glycoprotein located at the apical surface of glandular epithelial cells. In some tumors, MUC1 is often aberrantly over-expressed and hypoglycosylated, unmasking new antigenic epitopes. This makes it a potential target for tumor-specific vaccination. In renal cell carcinoma (RCC), MUC1 expression is associated with a poor prognosis. TG4010 is a cancer vaccine based on a modified vaccinia virus (MVA) expressing both MUC1 and Interleukin 2. The phase II study objective was to determine the overall response rate of TG4010 alone and in combination with cytokines in a two-step design. Methods: Patients (pts) with progressive metastatic RCC, expressing MUC1 in at least 50% of the tumour cells, received subcutaneous injections of TG4010 weekly for 6 weeks then every 3 weeks until progression, then the TG4010 was combined with Interferon alpha-2a (INF) and Interleukin 2 (IL2). Response to treatment was evaluated every 12 weeks according to the RECIST criteria. Median time to progression...
- Published
- 2005
- Full Text
- View/download PDF
21. Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC)
- Author
-
S. Kalla, Philippe Bougnoux, Thierry Petit, F. Ringeisen, Olivier Rixe, Catherine Lhommé, Patricia Pautier, Florence Joly, Pierre Kerbrat, and P. Fumoleau
- Subjects
Cisplatin ,Gynecology ,Cancer Research ,medicine.medical_specialty ,business.industry ,ECOG Performance Status ,Phases of clinical research ,Gastroenterology ,Carboplatin ,chemistry.chemical_compound ,Gefitinib ,Oncology ,chemistry ,Paclitaxel ,Internal medicine ,Ovarian carcinoma ,Toxicity ,medicine ,business ,medicine.drug - Abstract
5015 Background: EGFR expression is increased in 35–70% of primary OC, and often correlates with poor prognosis. Gefitinib (Iressa, ZD1839) is an orally active EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor). Methods: Multicenter, open, non-comparative study in pts with platinum-resistant (relapsed 6 months) OC, with measurable disease, or non-measurable disease with rising CA125, and after only one line-therapy with cisplatin or C, and P. Pts received gefitinib (500 mg/day), P (175 mg/m2), and C (AUC=5) every 3 weeks, for 6–8 cycles. After which, pts could continue to receive gefitinib. Response was assessed by RECIST or Rustin criteria. Results: Since April 2002, 41 pts (median age: 58 yrs (range 34–71)) and an ECOG performance status (0/1/2) of 27/14/0, were enrolled. In 40 assessed pts, 7 were non-evaluable for efficacy (early withdrawal (1), toxicity (2), no target lesions (4)). The overall response rates (CR and PR) were 25% and 71% i...
- Published
- 2004
- Full Text
- View/download PDF
22. Paraneoplastic Pemphigus with Constrictive Bronchiolitis obliterans
- Author
-
Selim Aractingi, N. Cordel, Jacques Cadranel, Martine Antoine, and F. Ringeisen
- Subjects
medicine.medical_specialty ,Paraneoplastic pemphigus ,business.industry ,medicine ,Dermatology ,medicine.disease ,Constrictive Bronchiolitis ,business - Published
- 2001
- Full Text
- View/download PDF
23. Interfacial reaction between disilane and a Ge(111) surface
- Author
-
D. Steinmetz, S. Van, F. Ringeisen, D. Bolmont, and J.J. Koulmann
- Subjects
Materials Chemistry ,Surfaces and Interfaces ,Condensed Matter Physics ,Surfaces, Coatings and Films - Published
- 1991
- Full Text
- View/download PDF
24. A photoemission investigation of the Si-Au interface and its behaviour under oxygen exposure
- Author
-
J. Derrien and F. Ringeisen
- Subjects
Metal ,Materials science ,X-ray photoelectron spectroscopy ,Interface (Java) ,visual_art ,visual_art.visual_art_medium ,Analytical chemistry ,Materials Chemistry ,Surfaces and Interfaces ,OXYGEN EXPOSURE ,Condensed Matter Physics ,Layer (electronics) ,Surfaces, Coatings and Films - Abstract
Using UPS and XPS techniques, we have focused our attention on the behaviour of Si atoms which have segregated at the topmost layer of the Si-Au interface. We have demonstrated that these Si atoms, without their usual sp 3 configuration, in a metallic environment, can be very easily oxidized even at room temperature.
- Published
- 1983
- Full Text
- View/download PDF
25. Interfacial reaction between monosilane and a polycrystalline tantalum substrate
- Author
-
F. Ringeisen, M. Alaoui, D. Muller, D. Bolmont, and J.J. Koulmann
- Subjects
Materials science ,Diffusion barrier ,Silicon ,Annealing (metallurgy) ,Tantalum ,Analytical chemistry ,General Physics and Astronomy ,chemistry.chemical_element ,Surfaces and Interfaces ,General Chemistry ,Atmospheric temperature range ,Condensed Matter Physics ,Surfaces, Coatings and Films ,Overlayer ,Crystallography ,chemistry ,X-ray photoelectron spectroscopy ,Surface layer - Abstract
We report XPS results on the thermal cracking of monosilane on a polycrystalline tantalum substrate. Ta substrates were heated in the 20°C–800°C temperature range and exposed to low pressure (10−5 Torr) SiH4 doses. We followed the Ta/TaSi2 interface growth by recording the Si2p and Ta4f core level shifts. For temperatures below 600°C, results show growth of a thin (∼ 15 A) TaSi2 film followed by a thin Si overlayer. By annealing at 750°C for 2 min, this Si surface layer intermixes with bulk tantalum. For preparation at higher temperatures (600°C–800°C), grown TaSi2 films get thicker (∼ 25 A) but the Ta/TaSi2 interface is always covered by a thin silicon overlayer. The growth process of the Ta/TaSi2 interface is limited by the diffusion coefficient of Ta through the TaSi2 film which acts as a diffusion barrier.
- Published
- 1989
- Full Text
- View/download PDF
26. Photoemission study of low pressure silane adsorption on Si(111)7 × 7
- Author
-
F. Ringeisen, D. Muller, D. Bolmont, and J.J. Koulmann
- Subjects
Photoemission spectroscopy ,Chemistry ,Analytical chemistry ,Surfaces and Interfaces ,Atmospheric temperature range ,Condensed Matter Physics ,medicine.disease_cause ,Silane ,Surfaces, Coatings and Films ,chemistry.chemical_compound ,Adsorption ,X-ray photoelectron spectroscopy ,Torr ,Materials Chemistry ,medicine ,Saturation (chemistry) ,Ultraviolet - Abstract
We present results on the thermal cracking of silane on Si(111) 7× 7 surface studied by ultraviolet (UPS) and X-ray (XPS) photoemission spectroscopy. Samples were heated in the temperature range 20°C-500°C and exposed to low pressure (10 −5 Torr) SiH 4 doses in the range 10 3 -10 5 L. Only characteristic signatures of mono and dihydride phases are evidenced. Forsilane saturation at 300 °C, the Si-H peak int the same temperature. Sticking of Si-H groups might occur atop of the rest-atoms of the DAS model.
- Published
- 1989
- Full Text
- View/download PDF
27. XPS, ESR and resistivity measurements on amorphous silicon oxynitride films (a-SiOxNy) prepared by reactive evaporation of Si in presence of NO2
- Author
-
A. Jaéglé, L. Kubler, R. Haug, and F. Ringeisen
- Subjects
Amorphous silicon ,Silicon oxynitride ,Materials science ,Photodissociation ,Analytical chemistry ,chemistry.chemical_element ,Condensed Matter Physics ,Oxygen ,Evaporation (deposition) ,Electronic, Optical and Magnetic Materials ,chemistry.chemical_compound ,chemistry ,X-ray photoelectron spectroscopy ,Electrical resistivity and conductivity ,Materials Chemistry ,Ceramics and Composites ,Ternary operation - Abstract
Silicon oxynitride films (SiOxNy) are prepared by reactive, electron gun evaporation of Si at nitrogen dioxide pressures ranging from 10−6 T to 5 × 10−5 T. In this way the brightness of W-filament of the electron gun probably contributes to the photodissociation of NO2 and favours the introduction of oxygen. The oxygen composition, determined by XPS analysis, may be varied nearly over the entire range between Si and SiO2 (O < x < 2), that of the nitrogen remaining limited (y < 0.4) Starting from pure a-Si, with rising NO2 pressures and oxygen content, the resistivity and the optical transmission vary gradually — as for a-SiOx samples — to insulating and transparent samples. The XPS Si2p electron energy shift and the ESR g-value shift are also well connected with the composition and the local surroundings of the Si atoms. The behaviour of thse spectra versus the composition provides arguments for a description of the structure of the SiOxNy films with a ternary random bonding model and local bondings of the kind |Si-(Si4−X−YOXNY)| (X or Y = 0, 1, 2, 3, but Y is generally less than X, X + Y ⩽ 4). On the other hand the ESR spin density remains high (1018–1019 cm−3) if care is taken in its determination, and is not related to the conduction and the sample composition for high x values, but seems to be connected with the method of preparation.
- Published
- 1983
- Full Text
- View/download PDF
28. Hydrogenation of amorphized silicon by low energy H+ ion bombardment studied by UPS
- Author
-
F. Ringeisen, D. Muller, D. Bolmont, and J.J. Koulmann
- Subjects
Silicon ,Hydrogen ,Physics::Instrumentation and Detectors ,Chemistry ,Photoemission spectroscopy ,Fermi level ,Analytical chemistry ,chemistry.chemical_element ,General Chemistry ,Condensed Matter Physics ,symbols.namesake ,Low energy ,Ion implantation ,Phase (matter) ,Materials Chemistry ,symbols ,Wafer ,Nuclear chemistry - Abstract
We studied the influence of low energy (1–3 keV) H+ ion bombardment on amorphized silicon wafers. Mainly monohydride phase formation is evidenced by Ultra-violet Photoemission Spectroscopy (UPS). When previously formed mono and polyhydride phases coexist, the polyhydride phase is preferentially etched by H+ bombardment.
- Published
- 1989
- Full Text
- View/download PDF
29. STRUCTURE AND GROWTH KINETICS OF SiO2 ULTRA THIN FILM ON Si(111) SURFACE
- Author
-
F. Ringeisen, M. Commandre, and J. Derrien
- Subjects
chemistry.chemical_compound ,Materials science ,Silicon ,chemistry ,X-ray photoelectron spectroscopy ,Covalent bond ,Phenomenological model ,Analytical chemistry ,Oxide ,chemistry.chemical_element ,Thin film ,Silicon oxide ,Layer (electronics) - Abstract
The structure and the growth of very thin films of silicon oxide on top of atomically clean silicon surfaces have been investigated with surface techniques such as AES, ELS, LEED and XPS under UHV conditions. A transition layer was found to form at the Si-Si02 interface. The growth kinetics could be explained by a phenomenological model based on oxygen diffusion through the oxide layer under the presence of a surface electric field. Finally the Si oxidation has also been examined with XPS technique when some metallic impurities were evaporated onto the Si surface prior to oxygen exposure. An enhanced reactivity was observed and attributed to the covalent sp3 bond disruption which was provoked by metallic impurities.
- Published
- 1983
- Full Text
- View/download PDF
30. Broken-dimer model in a-Si:H
- Author
-
D. Bolmont, F. Ringeisen, J. J. Koulmann, and D. Muller
- Subjects
chemistry.chemical_compound ,Crystallography ,Materials science ,chemistry ,Photoemission spectroscopy ,Dimer - Published
- 1989
31. HYDROGENATION OF AMORPHIZED SILICON STUDIED BY UPS
- Author
-
D. Muller, D. Bolmont, J.J. Koulmann, and F. Ringeisen
- Subjects
Materials science ,Hydrogen ,Silicon ,Photoemission spectroscopy ,Analytical chemistry ,chemistry.chemical_element ,Condensed Matter Physics ,Electronic, Optical and Magnetic Materials ,Crystallography ,Adsorption ,chemistry ,X-ray photoelectron spectroscopy ,Phase (matter) ,Monolayer ,Materials Chemistry ,Ceramics and Composites ,Absorption (chemistry) - Abstract
Recent studies have revealed interesting properties of the dihydride phase coexisting with the monohydride phase on the hydrogenated Si surface. The absorption of atomic hydrogen on amorphized (i.e. Ar+ ion bombarded) silicon has been studied for coverages at and below one monolayer at temperatures between 300 K and 600 K using photoemission spectroscopy (UPS and XPS). In the very first stages of room temperature (RT) adsorption (< 50 L), we detected only the monohydride phase while dihydride phase formation is observed for exposures above 50 L. For T ≥ 600 K, only the monohydride phase is present at all exposures. Experimental evidence that the adsorption sites for the SiH2 states are not produced by corrosion is presented. Identical results were obtained on amorphized Si (111) and Si (100).
32. REVERSIBLE PROCESS OF HYDROGEN ADSORPTION ON SI(111)
- Author
-
D. Bolmont, F. Ringeisen, J.J. Klulmann, and D. Muller
- Subjects
Hydrogen ,Chemistry ,Photoemission spectroscopy ,Analytical chemistry ,chemistry.chemical_element ,Reversible process ,Surfaces and Interfaces ,Condensed Matter Physics ,Hydrogen adsorption ,Surfaces, Coatings and Films ,Adsorption ,X-ray photoelectron spectroscopy ,Phase (matter) ,Monolayer ,Materials Chemistry - Abstract
Recent studies have revealed interesting properties of the dihydride phase coexisting with the monohydride phase on the hydrogenated Si surface. The adsorption of atomic hydrogen on the Si(111)7×7 surface has been studied for coverages at and below one monolayer at temperatures between 300 and 600 K using photoemission spectroscopy (UPS and XPS). In the very first stages of room temperature (RT) adsorption (
33. Band bending variation of the Si(111) surface during its thermal oxidation
- Author
-
J. Derrien and F. Ringeisen
- Subjects
In situ ,Thermal oxidation ,Auger electron spectroscopy ,Band bending ,Low-energy electron diffraction ,Photoemission spectroscopy ,Chemistry ,Binding energy ,Ultra-high vacuum ,Materials Chemistry ,Analytical chemistry ,General Chemistry ,Condensed Matter Physics - Abstract
During the thermal oxidation of Si(111) surfaces performed under ultra high vacuum conditions and investigated with various surface techniques such as Auger electron spectroscopy, low energy electron diffraction, ultra violet and X-ray induced photoemission spectroscopy, the Si 2p core level binding energy was measured and provided directly the band bending variation of the Si surface. A net interface charge then could be deduced. This is an elegant in situ method to have access to the electrical characteristics of the SiSiO2 interface during its formation.
- Published
- 1984
- Full Text
- View/download PDF
34. ÉTUDE PAR PHOTOÉMISSION DE L'ADSORPTION DE DISILANE SUR Si (111) 7x7
- Author
-
J.J. Koulmann, M. Alaoui, D. Muller, D. Bolmont, and F. Ringeisen
- Subjects
General Engineering - Published
- 1989
- Full Text
- View/download PDF
35. Formation and properties of the copper silicon(111) interface
- Author
-
J. Derrien, F. Salvan, E. Daugy, Ph. Mathiez, J. M. Layet, and F. Ringeisen
- Subjects
Auger electron spectroscopy ,Valence (chemistry) ,chemistry ,X-ray photoelectron spectroscopy ,Silicon ,Layer by layer ,Binding energy ,General Engineering ,Analytical chemistry ,chemistry.chemical_element ,Crystal growth ,Copper - Abstract
The initial stages of the Cu growth on top of a 7×7 Si(111) surface were monitored with LEED, AES, UPS, and XPS techniques. Results suggest that at room temperature the Cu growth proceeds by a laminar fashion. An intermixing between Si and Cu takes place giving rise to a diffuse interface extending to several first monolayers. This fact is testified by the splitting of the Si LVV transition in AES spectra, by the deviation of the AES and XPS Cu and Si signal plot versus coverage from a perfect layer by layer growth plot, and by a strong diffuse background intensity in LEED diagram. Moreover, at this coverage range, a slight narrowing and a shift (0.7 eV±0.2 eV) of the 3d Cu peak towards higher binding energy as compared with the bulk metal are observed in valence band photoemission spectra. With increasing coverage, a metal rich phase is found displaying an ordered 1×1 Cu(111) planelike structure. No Si enrichment at the topmost metallic layer is observed by XPS. Core level spectroscopy gives similar resu...
- Published
- 1983
- Full Text
- View/download PDF
36. Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
- Author
-
Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, Ostojic H, Ringeisen F, and Pivot X
- Subjects
- Activities of Daily Living, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Patient Reported Outcome Measures, Prognosis, Receptor, ErbB-2 therapeutic use, Receptors, Estrogen therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms epidemiology
- Abstract
Background: Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) and disease-related poor prognostic factors are not well characterized. We aimed to describe patient demographics, disease characteristics, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- ABC patients with these factors [at the time when cyclin-dependent kinase (CDK) 4 and 6 inhibitors were being introduced] and understand how these factors informed treatment decisions at the time of the survey., Methods: Real-world data were derived from a large, multinational, point-in-time survey of oncologists and their consulting patients with HR+/HER2- ABC in the EU5 and USA over March-June 2017, at the start of the changing treatment landscape. Analysis focused on four poor prognostic factors: visceral metastases, liver metastases (subset of visceral metastases), progesterone receptor-negative status and high tumor grade., Results: In total, 2259 patients with HR+/HER2- ABC had records eligible for this analysis. At least one poor prognostic factor was present in 63% of patients (most common visceral metastases; least common progesterone receptor-negative status), with varying degrees of overlap between factors. For physician-reported outcomes, pain increased, whereas performance status and activities of daily living declined with presence of poor prognostic factors, especially liver metastases. No clear trends were observed for patient-reported outcomes. Treatment with combined endocrine therapy plus CDK4 and 6 inhibitors was infrequent, as these agents were entering the market., Conclusions: More than 60% of the HR+/HER2- ABC Adelphi Real World Disease Specific Programme™ sample had ≥1 disease-related poor prognostic factor, and patients appeared to be heterogeneous regarding occurrence and distribution of these factors. These patients typically have increased pain and reduced performance status, highlighting the importance of implementing effective therapy with CDK4 and 6 inhibitors. Future studies could inform how the treatment landscape has evolved over time with respect to patients with poor prognostic factors., Competing Interests: Disclosure AD, GCC and GP have disclosed that they are employees of Eli Lilly and Company. FR and HO have disclosed they were employees of Eli Lilly and Company during the development of the analysis. AB, AR and KL have disclosed that they are employees of Adelphi Real World Ltd, who own the multi-sponsored Disease Specific Programme, and were paid by Eli Lilly and Company Ltd in the development of this analysis and manuscript. XP has disclosed an advisory role with Eli Lilly and Company, for which an honorarium was received from Eli Lilly and Company Ltd for consultancy support in the development of this analysis., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
- Author
-
Martin M, Garcia-Saenz JA, Manso L, Llombart A, Cassinello A, Atienza M, Ringeisen F, and Ciruelos E
- Subjects
- Aminopyridines pharmacology, Benzimidazoles pharmacology, Biomarkers, Tumor, Breast Neoplasms etiology, Breast Neoplasms metabolism, Breast Neoplasms mortality, Female, Humans, Molecular Targeted Therapy, Prognosis, Protein Kinase Inhibitors pharmacology, Treatment Outcome, Aminopyridines therapeutic use, Benzimidazoles therapeutic use, Breast Neoplasms drug therapy, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Protein Kinase Inhibitors therapeutic use
- Abstract
The addition of CDK4 and 6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective response rates and in some trials overall survival, compared with endocrine therapy alone in HR+ and HER2- breast metastatic breast cancer. These CDK4 and 6 inhibitors are now approved in this context and have become a new standard of care. A hypothesis-generating exploratory analysis suggested that the addition of abemaciclib to endocrine therapy showed the largest effects in subgroups of women with indicators of poor prognosis, although these data require confirmation. This review provides updated clinical trial data for all three drugs in metastatic breast cancer, focusing on abemaciclib, the most recently approved agent.
- Published
- 2020
- Full Text
- View/download PDF
38. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
- Author
-
Davie A, Carter GC, Rider A, Pike J, Lewis K, Bailey A, Price GL, Ringeisen F, and Pivot X
- Subjects
- Adult, Aged, Bone Neoplasms pathology, Bone Neoplasms secondary, Breast Neoplasms genetics, Breast Neoplasms pathology, Europe epidemiology, Female, Humans, Liver Neoplasms pathology, Liver Neoplasms secondary, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Receptor, ErbB-2 genetics, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bone Neoplasms drug therapy, Breast Neoplasms drug therapy, Liver Neoplasms drug therapy
- Abstract
Background: Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient symptoms and health-related quality of life (HRQoL) at the start of this changing therapeutic landscape. This real-world study describes the patient-reported outcomes (PROs) of women with HR+/HER2- advanced breast cancer receiving ET-based regimens who were naïve to systemic treatment in the advanced setting across five European countries (EU5)., Methods: Data were collected between March and July 2017 from surveyed oncologists and their patients at a single time point using the multinational Adelphi Advanced Breast Cancer Disease Specific Programme™. Patients completed PRO questionnaires on HRQoL (EORTC QLQ-C30), pain severity and interference, and work and activity impairment. A multiple linear regression model explored factors associated with HRQoL., Results: Across EU5, 226 physicians provided data on 781 women with HR+/HER2- advanced breast cancer taking their first ET-based regimen for advanced disease, of whom 252 provided PRO data. This subset had a mean age of 67.1 years, 94% were postmenopausal, 89% were diagnosed with advanced breast cancer at initial presentation, 79% had stage IV disease (66% of these patients had bone metastases and 38% had visceral metastases, including 18% with liver metastases) and 77% were on endocrine-only therapy as their initial treatment for advanced disease. The mean EORTC QLQ-C30 global health score (50.9) was worse than the reference value for patients with advanced breast cancer (60.2). Fatigue, pain, and insomnia were the most severe symptoms, and mean functioning scores were also worse than reference values. "Worst pain" and "pain interference" were moderate/severe for 42 and 80% of patients. Mean activity impairment was 44%, and greater activity impairment was associated with poorer HRQoL., Conclusions: Despite receiving first-line ET-based regimens for advanced disease, these women had a poor HRQoL and high levels of symptoms, pain, pain interference and activity impairment. New treatments that maintain a stable disease state and reduce activity impairment may have a positive effect on the HRQoL of those living with advanced breast cancer.
- Published
- 2020
- Full Text
- View/download PDF
39. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.
- Author
-
Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, and Jiang Z
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms metabolism, Breast Neoplasms mortality, Breast Neoplasms pathology, Everolimus administration & dosage, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Paclitaxel administration & dosage, Proportional Hazards Models, Receptor, ErbB-2 metabolism, Retreatment, Trastuzumab administration & dosage, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
Background: The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in the BOLERO-1 trial., Methods: Postmenopausal women with HER2+ advanced breast cancer, who had not received systemic therapy for advanced disease, were randomized 2:1 to receive everolimus or placebo, plus trastuzumab and paclitaxel. The two primary end points were investigator-assessed progression-free survival (PFS) in the full population and in the hormone receptor-negative (HR-) subpopulation. Secondary end points included assessment of the objective response rate, the clinical benefit rate, and safety., Results: In the Asian subset, median PFS was similar in the everolimus (n = 198) and placebo (n = 105) arms in the full analysis set (hazard ratio = 0.82 (95% CI 0.61-1.11)). In the HR- subpopulation, everolimus prolonged median PFS by 10.97 months vs placebo (25.46 vs 14.49 months; hazard ratio = 0.48 (95% CI 0.29-0.79)). In the everolimus arm of the Asian subset, the most common adverse events of any grade were stomatitis (62.2%), diarrhea (48.0%), rash (43.4%) and neutropenia (42.3%). Neutropenia (grade 3: 27.6%; grade 4: 4.6%) and decreased neutrophil count (grade 3: 11.2%; grade 4: 3.6%) were the most frequent grade 3/4 adverse events. Serious adverse events included pneumonia (5.1%), pneumonitis (3.1%), and interstitial lung disease (3.1%). There were three deaths (1.5%) during treatment in the everolimus arm vs none in the placebo arm., Conclusions: The efficacy and safety of everolimus plus trastuzumab and paclitaxel as first-line treatment for HER2+ advanced breast cancer in the Asian subset was consistent with that reported previously in the overall population., Trial Registration: ClinicalTrials.gov, NCT00876395 . Registered on 2 April 2009.
- Published
- 2017
- Full Text
- View/download PDF
40. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2 - advanced breast cancer: results from BOLERO-2.
- Author
-
Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, and Chandarlapaty S
- Subjects
- Androstadienes administration & dosage, Biomarkers, Tumor blood, Biomarkers, Tumor metabolism, Breast Neoplasms blood, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cell-Free System, Class I Phosphatidylinositol 3-Kinases, DNA Mutational Analysis, Everolimus administration & dosage, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Breast Neoplasms genetics, DNA, Neoplasm blood, DNA, Neoplasm genetics, Mutation genetics, Phosphatidylinositol 3-Kinases genetics
- Abstract
Background: The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation., Methods: PIK3CA H1047R, E545K, and E542K mutations in plasma-derived cfDNA were analysed by droplet digital PCR (ddPCR). Median PFS was estimated for patient subgroups defined by PIK3CA mutations in each treatment arm., Results: Among 550 patients included in cfDNA analysis, median PFS in everolimus vs placebo arms was similar in patients with tumours that had wild-type or mutant PIK3CA (hazard ratio (HR), 0.43 and 0.37, respectively). Everolimus also prolonged median PFS in patients with PIK3CA H1047R (HR, 0.37) and E545K/E542K mutations (HR=0.30) with a similar magnitude., Conclusions: Mutation analysis of plasma-derived cfDNA by ddPCR suggests that PFS benefit of everolimus was maintained irrespective of PIK3CA genotypes, consistent with the previous analysis of archival tumour DNA by next-generation sequencing.
- Published
- 2017
- Full Text
- View/download PDF
41. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
- Author
-
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, and Wolf J
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Antineoplastic Agents pharmacokinetics, Female, Humans, Hyperphosphatemia chemically induced, Male, Maximum Tolerated Dose, Middle Aged, Phenylurea Compounds adverse effects, Phenylurea Compounds blood, Phenylurea Compounds pharmacokinetics, Pyrimidines adverse effects, Pyrimidines blood, Pyrimidines pharmacokinetics, Antineoplastic Agents administration & dosage, Phenylurea Compounds administration & dosage, Pyrimidines administration & dosage, Receptors, Fibroblast Growth Factor genetics
- Abstract
Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients and Methods Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles. During expansion at the MTD, patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-weeks-on/1-week-off schedule (arm 3). Results Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff). The MTD, 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]). Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%). A similar safety profile was observed using the 3-weeks-on/1-week-off schedule (RP2D). However, adverse event-related dose adjustments/interruptions were less frequent with the 3-weeks-on/1-week-off (50.0%) versus the continuous (73.7%) schedule. Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer. Conclusion BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
- Published
- 2017
- Full Text
- View/download PDF
42. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
- Author
-
Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, and Motzer R
- Subjects
- Antineoplastic Agents therapeutic use, Disease-Free Survival, Everolimus therapeutic use, Humans, Immunosuppressive Agents therapeutic use, Neoplasms drug therapy, Stomatitis epidemiology, Tuberous Sclerosis drug therapy, Antineoplastic Agents adverse effects, Everolimus adverse effects, Immunosuppressive Agents adverse effects, Mucous Membrane pathology, Stomatitis chemically induced, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Background: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, is used to treat solid tumors and tuberous sclerosis complex (TSC). Stomatitis, an inflammation of the mucous membranes of the mouth, is a common adverse event associated with mTOR inhibitors, including everolimus. We conducted a meta-analysis of data from seven randomized, double-blind phase 3 clinical trials of everolimus to determine the clinical impact of stomatitis on efficacy and safety., Patients and Methods: Data were pooled from the safety sets of solid tumor [breast cancer (BOLERO-2 and BOLERO-3), renal cell carcinoma (RECORD-1), carcinoid tumors (RADIANT-2), and pancreatic neuroendocrine tumors (RADIANT-3)] and TSC studies (EXIST-1 and EXIST-2). Data from solid tumor trials and TSC trials were analyzed separately., Results: The rate of stomatitis was 67% in the solid tumor trials (973/1455 patients) and 70% in the TSC trials (110/157 patients). Most stomatitis events were grade 1/2, with grade 3/4 events reported in only 9% (solid tumor trials) and 8% (TSC trials) of patients. Low TSC patient numbers prevented an in-depth evaluation of stomatitis and response. In the solid tumor trials, most first stomatitis episodes (89%; n = 870) were observed within 8 weeks of starting everolimus. Patients with stomatitis occurring within 8 weeks of everolimus initiation had longer progression-free survival (PFS) than everolimus-treated patients without stomatitis in BOLERO-2 {8.5 versus 6.9 months, respectively; hazard ratio (HR), 0.78 [95% confidence interval (CI), 0.62-1.00]} and RADIANT-3 [13.9 versus 8.3 months, respectively; HR, 0.70 (95% CI, 0.48-1.04)]. A similar trend was observed in RECORD-1 [HR, 0.90 (95% CI, 0.66-1.22)] and RADIANT-2 [HR, 0.87 (95% CI, 0.61-1.22)] but not in BOLERO-3 [HR, 1.01 (95% CI, 0.75-1.36)]., Conclusions: Stomatitis did not adversely affect PFS, supporting the administration of everolimus in accordance with standard management guidelines., (© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
43. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
- Author
-
Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, and Piccart M
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Breast Neoplasms genetics, Breast Neoplasms pathology, Clinical Trials as Topic, Disease-Free Survival, Everolimus, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Neoplasms, Hormone-Dependent genetics, Neoplasms, Hormone-Dependent pathology, Receptors, Estrogen genetics, Receptors, Progesterone genetics, Sirolimus administration & dosage, Androstadienes administration & dosage, Breast Neoplasms drug therapy, Neoplasms, Hormone-Dependent drug therapy, Sirolimus analogs & derivatives
- Abstract
The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (HR(+)), human epidermal growth factor receptor-2-negative (HER2(-)) advanced breast cancer recurring/progressing after a nonsteroidal aromatase inhibitor (NSAI) were randomly assigned (2:1) to receive EVE (10 mg/day) + EXE (25 mg/day) or placebo (PBO) + EXE. The primary endpoint was progression-free survival (PFS) by local assessment. Overall, 137 patients received first-line EVE + EXE (n = 100) or PBO + EXE (n = 37). Median PFS by local investigator assessment nearly tripled to 11.5 months with EVE + EXE from 4.1 months with PBO + EXE (hazard ratio = 0.39; 95 % CI 0.25-0.62), while maintaining quality of life. This was confirmed by central assessment (15.2 vs 4.2 months; hazard ratio = 0.32; 95 % CI 0.18-0.57). The marked PFS improvement in patients receiving EVE + EXE as first-line therapy for disease recurrence during or after (neo)adjuvant NSAI therapy supports the efficacy of this combination in the first-line setting. Furthermore, the results highlight the potential benefit of early introduction of EVE + EXE in the management of HR(+), HER2(-) advanced breast cancer in postmenopausal patients.
- Published
- 2014
- Full Text
- View/download PDF
44. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
- Author
-
Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich RT, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, and Thomas RK
- Subjects
- Animals, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Cell Line, Cell Transformation, Neoplastic metabolism, Chromosomes, Human, Pair 8, Disease Models, Animal, Gene Expression, Gene Expression Profiling, Genes, myc, Genetic Heterogeneity, Heterografts, Humans, Ligands, Lung Neoplasms diagnosis, Lung Neoplasms metabolism, Lung Neoplasms therapy, Mice, Receptor, Fibroblast Growth Factor, Type 1 metabolism, Signal Transduction, Treatment Outcome, Cell Transformation, Neoplastic genetics, Gene Amplification, Lung Neoplasms genetics, Receptor, Fibroblast Growth Factor, Type 1 genetics
- Abstract
Unlabelled: The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, in contrast with other recurrent amplifications, the 8p12 region included multiple centers of amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands in vitro and in vivo. Furthermore, ectopic expression of FGFR1 was oncogenic, which was enhanced by expression of MYC. We found that MYC was coexpressed in 40% of FGFR1-amplified tumors. Tumor cells coexpressing MYC were more sensitive to FGFR inhibition, suggesting that patients with FGFR1-amplified and MYC-overexpressing tumors may benefit from FGFR inhibitor therapy. Thus, both cell-autonomous and non-cell-autonomous mechanisms of transformation modulate FGFR dependency in FGFR1-amplified lung cancer, which may have implications for patient selection for treatment with FGFR inhibitors., Significance: Amplification of FGFR1 is one of the most frequent candidate targets in lung cancer. Here, we show that multiple factors affect the tumorigenic potential of FGFR1, thus providing clinical hypotheses for refinement of patient selection., (2013 AACR)
- Published
- 2014
- Full Text
- View/download PDF
45. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
- Author
-
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, and Tartour E
- Subjects
- Adolescent, Adult, Aged, Cancer Vaccines administration & dosage, Carcinoma, Renal Cell immunology, Cell Proliferation, Cytokines administration & dosage, Disease Progression, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Kidney Neoplasms immunology, Male, Membrane Glycoproteins administration & dosage, Middle Aged, Mucin-1 biosynthesis, Mucin-1 immunology, Neoplasm Metastasis pathology, Neoplasm Metastasis therapy, Treatment Outcome, Young Adult, Cancer Vaccines immunology, Cancer Vaccines therapeutic use, Carcinoma, Renal Cell pathology, Carcinoma, Renal Cell therapy, Cytokines immunology, Cytokines therapeutic use, Kidney Neoplasms pathology, Kidney Neoplasms therapy, Membrane Glycoproteins immunology, Membrane Glycoproteins therapeutic use
- Abstract
MUC1 over-expression in renal clear-cell carcinoma (RCC) is associated with poor prognosis. This phase II study determined the efficacy and tolerability of TG4010, a cancer vaccine based on a modified vaccinia virus expressing MUC1 and interleukin-2, in combination with cytokines, as first-line therapy in metastatic RCC. Thirty-seven patients with progressive, MUC1-positive RCC received TG4010 10(8) pfu/inj weekly for 6 weeks, then every 3 weeks until progression, when TG4010 was continued in combination with interferon-α2a and interleukin-2. Assessments included clinical response (primary endpoint), safety, time to treatment failure (TTF), overall survival (OS), and immune response. No objective clinical responses occurred. Five of the 27 evaluable patients (18%) had stable disease for >6 months with TG4010 alone and six of 20 patients (30%) had stable disease for >6 months with TG4010 plus cytokines. Median TTF was 4.1, 3.6, and 9.3 months for monotherapy, combination therapy, and overall, respectively. Median OS was 19.3 months for all patients and 22.4 months combination therapy recipients. The most frequent TG4010-related adverse events were minor-to-moderate injection-site reactions, fatigue, and flu-like symptoms. Six of 28 patients showed a MUC1 CD4+ T cell proliferative response during therapy. Anti-MUC1 CD8+ T cells were detected before and after therapy in 3 and 4 patients, respectively. MUC1-specific CD8+ T cell responses were associated with longer survival. Therapy with TG4010 plus cytokines appears to be feasible and well tolerated in patients with metastatic RCC. However, these data should be interpreted with caution, as additional prospective studies are necessary to clarify the clinical efficacy of this therapy.
- Published
- 2011
- Full Text
- View/download PDF
46. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
- Author
-
Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, and Lhommé C
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin administration & dosage, Carboplatin adverse effects, Disease-Free Survival, Female, Gefitinib, Humans, Middle Aged, Paclitaxel administration & dosage, Paclitaxel adverse effects, Quinazolines administration & dosage, Quinazolines adverse effects, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Fallopian Tube Neoplasms drug therapy, Ovarian Neoplasms drug therapy, Peritoneal Neoplasms drug therapy
- Abstract
Objective: This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma., Patients and Methods: Women (>18 years) with platinum-resistant/refractory (relapsed<6 months), or platinum-sensitive (relapsed >6 months) disease after first-line platinum-based and P chemotherapy. Pts received 6-8 cycles of gefitinib (500 mg/day), P (175 mg/m(2) 3 h infusion) and C (AUC 5) every 3 weeks, followed by gefitinib alone. The primary endpoint was objective response rate (ORR) (RECIST or Rustin criteria)., Results: Sixty-eight patients (26 resistant/refractory and 42 sensitive) were enrolled (median age: 57 years). ORR and disease control rates were 19.2% and 69.2% for resistant/refractory, and 61.9% and 81.0%, for sensitive disease. Median time to progression and overall median survivals were 6.1 and 16.9 months for resistant/refractory and 9.2 and 25.7 months for sensitive disease. Grade 3/4 toxicities (in > or = 10% patients) were neutropenia (59%), diarrhea (25%), leukopenia (22%), anemia (13%), and acne (13%). Two secondary myelodysplastic syndromes (MDS) and one secondary acute leukemia occurred during treatment, and one MDS 34 months after treatment discontinuation., Conclusion: Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders., (Copyright 2009 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
47. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer.
- Author
-
Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, and Cochet C
- Subjects
- Aged, Aged, 80 and over, Biopsy, Blotting, Western, Catalytic Domain, Humans, Immunohistochemistry, Male, Middle Aged, Prognosis, RNA, Small Interfering metabolism, Casein Kinase II metabolism, Neoplasm Proteins metabolism, Prostate pathology, Prostatic Neoplasms metabolism
- Abstract
Many genomic abnormalities have been identified in various subsets of prostate cancer, but until now, few genes have been associated with the progression of this cancer. High activity of protein serine/threonine kinase CK2 has been observed in various solid tumours and this alteration has been linked both to growth-related functions and to suppression of cellular apoptosis. Here, we provide the first evidence for a strong association between a nuclear localization of CK2alpha, evaluated by immunohistochemistry, and poor prognostic factors in a retrospective cohort of 131 human prostate adenocarcinomas. Nuclear CK2alpha localization is significantly correlated with higher Gleason score, more locally advanced disease (cT3-T4) and more perineural or lymphatic invasion (p<0.0019 to 0.046). In contrast, despite a strong trend, no significant relationship was found between higher initial PSA and nuclear CK2alpha localization. Thus, this previously undescribed molecular heterogeneity is the first step in defining CK2 as both a potential biomarker and a promising target in human prostate cancer.
- Published
- 2007
- Full Text
- View/download PDF
48. [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].
- Author
-
Bolla M, Artignan X, Fourneret P, Brochon D, Ringeisen F, and Descotes JL
- Subjects
- Androgen Antagonists therapeutic use, Humans, Male, Neoplasms, Hormone-Dependent pathology, Prostatic Neoplasms pathology, Randomized Controlled Trials as Topic, Antineoplastic Agents, Hormonal therapeutic use, Neoadjuvant Therapy methods, Neoplasms, Hormone-Dependent drug therapy, Neoplasms, Hormone-Dependent radiotherapy, Prostatic Neoplasms drug therapy, Prostatic Neoplasms radiotherapy
- Abstract
RTOG and EORTC trials have paved the way of the combination of radiation therapy and androgen suppression. Localized carcinoma with intermediate prognostic factors (cT2b, Gleason 7, or baseline PSA ranging between 10 and 20 ng/mL) may be submitted to a 4-month complete androgene blockade with 2 months before irradiation, unless to include patients in ongoing randomized trials. High risk cancers (cT2c, or Gleason > 7, or PSA > 20 ng/ml) should receive a 4-month or 6-month complete androgen blockade (RTOG trial 86-10), knowing that the results of EORTC trial 22961 are eagerly expected to tell us whether a 3- year androgen suppression is preferable. Very high risk prostate cancers, T3-4 N0 M0 or pelvic lymph node involvement (c or pN1) whatever the UICC T stage, need a long term androgen suppression of 3 years or more.
- Published
- 2006
49. [Breast carcinoma with predominant neuroendocrine differentiation].
- Author
-
Frachon S, Pasquier D, Treilleux I, Seigneurin D, Ringeisen F, Rosier P, Bolla M, and Boutonnat J
- Subjects
- Biomarkers, Tumor analysis, Bone Neoplasms chemistry, Breast Neoplasms chemistry, Breast Neoplasms drug therapy, Breast Neoplasms radiotherapy, Breast Neoplasms surgery, Carcinoma, Ductal, Breast chemistry, Carcinoma, Neuroendocrine chemistry, Carcinoma, Neuroendocrine pathology, Cell Differentiation, Chemotherapy, Adjuvant, Chromogranin A, Chromogranins analysis, Combined Modality Therapy, Disease Progression, Female, Humans, Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoplasm Proteins analysis, Neural Cell Adhesion Molecules analysis, Radiotherapy, Adjuvant, Sternum chemistry, Synaptophysin analysis, Bone Neoplasms secondary, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Neuroendocrine secondary, Neoplastic Stem Cells pathology, Sternum pathology
- Abstract
Neuroendocrine differentiation can be identified in a subset of human breast carcinomas, either as scattered cells or as a predominant neuroendocrine component. We report a case of an invasive breast carcinoma largely composed of neuroendocrine cells. Eight years after a left mammary lumpectomy for a pT2N1MO SBR III invasive ductal carcinoma, a 67-years-old woman presented with a metastastic neuroendocrine sternal mass. To establish a relationship between mammary carcinoma and bone metastasis, histological slides of both the breast tumor and axillary lymph nodes were reviewed, and an immunohistochemical study was performed. They showed that: a) the mammary carcinoma was composed of a majority of small and large neuroendocrine cells synaptophysin +, NCAM+, chromogranin - (80%), associated with 2 other differentiated non endocrine components, one of metaplastic squamous carcinoma (10%) and the other of ductal carcinoma (10%); b) 4 axillary lymph nodes were involved by the ductal component which contained few NCAM + but synaptophysin - cells; c) Estrogen and progesterone receptors and HER2 were negative in the breast tumor and the metastatic nodes. We discuss the histogenesis of composite mammary carcinomas with neuroendocrine differentiation, the outcome of each component and the prognostic relevance of such a diagnosis.
- Published
- 2004
- Full Text
- View/download PDF
50. Functional analysis of ground squirrel hepatitis virus enhancer II.
- Author
-
Fourel G, Ringeisen F, Flajolet M, Tiollais P, and Buendia MA
- Subjects
- Animals, Base Sequence, Humans, Molecular Sequence Data, Viral Core Proteins genetics, Enhancer Elements, Genetic genetics, Orthohepadnavirus genetics
- Abstract
We have characterized a major regulatory element of ground squirrel hepatitis virus (GSHV) located within a 90-nucleotide fragment of the core promoter upstream sequences and have compared its organization to that of woodchuck hepatitis virus (WHV) enhancer II (We2). The GSHV element (Ge2) stimulates transcription from the viral core promoter and heterologous promoters in an orientation-independent manner but displays a lower level of activity than We2 in transient transfection assays in human hepatoma cells. The general organization of Ge2 into binding sites for the liver-enriched HNF-1 and HNF-4 proteins and for ubiquitous factors of the NF1 and Oct families was found to be mostly conserved with respect to the homologous We2 region. Accordingly, transactivation by HNF-1 and HNF-4 plays an essential role in the liver-specific transcriptional activity of both the GSHV and WHV core promoters. Distinctive features of the GSHV enhancer consist of its ability to bind C/EBP family factors in a central motif that overlaps with one of the two HNF-4 sites and its differential binding affinities for HNF-4.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.